<< Back

Jaguar Animal Health, Inc. Announces Pricing of Initial Public Offering

SAN FRANCISCO--(BUSINESS WIRE)--May 13, 2015-- Jaguar Animal Health, Inc. (Nasdaq: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today the pricing of its initial public offering of 2,860,000 shares of its common stock at a price to the public of $7.00 per share. All of the common stock is being offered by Jaguar Animal Health, Inc. The gross proceeds to Jaguar Animal Health, Inc. from the initial public offering are expected to be approximately $20,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Jaguar Animal Health, Inc. has granted the underwriters a 45-day option to purchase up to 429,000 additional shares of common stock to cover over-allotments, if any. The common stock of Jaguar Animal Health, Inc. has been approved for listing on the NASDAQ Capital Market and is expected to begin trading under the ticker symbol "JAGX" on May 13, 2015 at 11:15 AM, and the offering is expected to close on May 18, 2015, subject to customary closing conditions.

Aegis Capital Corp. is acting as sole book-running manager for the offering.

Feltl and Company and CRT Capital are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and declared effective on May 13, 2015.

This offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, via telephone: 212-813-1010, or via e-mail: prospectus@aegiscap.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Canalevia™ is Jaguar’s lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. Neonorm™ Calf is the company’s lead non-prescription product. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm is a standardized botanical extract derived from the Croton lechleri tree. Canalevia and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has filed nine Investigational New Animal Drug applications, or INADs, with the FDA and intends to develop species-specific formulations of Neonorm in six additional target species, and formulations of Canalevia for cats, horses and dogs.

Source: Jaguar Animal Health, Inc.

Investor and Media Contact
for Jaguar Animal Health, Inc.
Shari Annes, 650-888-0902